COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said it hoped to launch its insulin Tresiba in the United States three to five years from the time it starts cardiovascular trials. The company expects to start the trials within a year. Chief Financial Officer Jesper Brandgaard also told journalists that he expected the cost of the cardiovascular trials for Tresiba to be around $200 million to $300 million over a four to five year period. U.S. ... via Health News Headlines - Yahoo! News Read More Here..
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/05/novo-sees-us-tresiba-launch-3-5-yrs_1.html
No comments:
Post a Comment